BAY2862789
A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Advanced Solid TumorsNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 69
- Registration Number
- NCT05858164
- Locations
- 🇺🇸
AdventHealth medical Group Oncology Research at Celebration, Celebration, Florida, United States
🇺🇸Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit, Detroit, Michigan, United States
🇺🇸University of Mississippi Medical Center | Shafi Group, Jackson, Mississippi, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath